Seigo Nakamura

7.7k total citations
233 papers, 4.3k citations indexed

About

Seigo Nakamura is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Seigo Nakamura has authored 233 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Oncology, 97 papers in Cancer Research and 59 papers in Pathology and Forensic Medicine. Recurrent topics in Seigo Nakamura's work include Breast Cancer Treatment Studies (83 papers), Breast Lesions and Carcinomas (55 papers) and HER2/EGFR in Cancer Research (42 papers). Seigo Nakamura is often cited by papers focused on Breast Cancer Treatment Studies (83 papers), Breast Lesions and Carcinomas (55 papers) and HER2/EGFR in Cancer Research (42 papers). Seigo Nakamura collaborates with scholars based in Japan, United States and China. Seigo Nakamura's co-authors include Naoki Hayashi, Hideko Yamauchi, Norikazu Masuda, Hiroji Iwata, Hiroshi Yagata, Kenjiro Aogi, Yasuo Ohashi, Shinji Ohno, Koyu Suzuki and Atsushi Yoshida and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Seigo Nakamura

219 papers receiving 4.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Seigo Nakamura Japan	34	2.3k	1.7k	833	761	753	233	4.3k
Joon Jeong South Korea	33	1.9k 0.8×	1.7k 1.0×	573 0.7×	1.1k 1.4×	677 0.9×	274	4.0k
Ingo Bauerfeind Germany	29	2.2k 1.0×	2.2k 1.3×	1.1k 1.3×	559 0.7×	1.0k 1.4×	103	4.4k
Brittany Harvey United States	11	2.5k 1.1×	1.7k 1.0×	549 0.7×	806 1.1×	765 1.0×	16	4.7k
Gloria Broadwater United States	42	3.1k 1.3×	1.8k 1.0×	592 0.7×	1.2k 1.5×	1.0k 1.3×	182	6.2k
Sherko Kümmel Germany	37	2.5k 1.1×	2.0k 1.1×	910 1.1×	521 0.7×	814 1.1×	227	5.0k
G. Bruce Mann Australia	37	2.3k 1.0×	1.4k 0.8×	873 1.0×	1.5k 2.0×	670 0.9×	185	5.2k
Takayuki Kinoshita Japan	34	1.9k 0.8×	2.1k 1.2×	1.1k 1.3×	900 1.2×	737 1.0×	174	4.2k
Chafika Mazouni France	30	2.3k 1.0×	2.5k 1.4×	877 1.1×	1.1k 1.4×	672 0.9×	124	5.2k
Hyeong‐Gon Moon South Korea	37	1.5k 0.7×	1.7k 1.0×	885 1.1×	997 1.3×	599 0.8×	214	4.3k
Peter Dubsky Austria	44	3.3k 1.4×	2.7k 1.6×	779 0.9×	1.0k 1.3×	1.2k 1.6×	153	6.0k

Countries citing papers authored by Seigo Nakamura

Since Specialization

Citations

This map shows the geographic impact of Seigo Nakamura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seigo Nakamura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seigo Nakamura more than expected).

Fields of papers citing papers by Seigo Nakamura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seigo Nakamura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seigo Nakamura. The network helps show where Seigo Nakamura may publish in the future.

Co-authorship network of co-authors of Seigo Nakamura

This figure shows the co-authorship network connecting the top 25 collaborators of Seigo Nakamura. A scholar is included among the top collaborators of Seigo Nakamura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seigo Nakamura. Seigo Nakamura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Takahashi, Masato, Tadashi Nomizu, Takanori Ishida, et al.. (2025). Analysis of the conditions for applying BRCA genetic testing to women with breast cancer using the Japanese HBOC consortium and the Japanese organization of hereditary breast and ovarian cancer (JOHBOC) registry project database. Breast Cancer. 32(4). 792–802.

Tokunaga, Eriko, Hiroji Iwata, Tatsuya Toyama, et al.. (2024). Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial. Breast Cancer. 32(1). 132–143. 2 indexed citations

Chishima, Takashi, Chie Watanabe, Mayuko Inuzuka, et al.. (2024). Development of a novel prediction model for carriage of BRCA1/2 pathogenic variant in Japanese patients with breast cancer based on Japanese organization of hereditary breast and ovarian cancer registry data. Breast Cancer Research and Treatment. 209(1). 177–188.

Verhoeven, Didier, Claudia Allemani, Pankaj G. Roy, et al.. (2024). High-value breast cancer care within resource limitations. The Oncologist. 29(7). e899–e909. 3 indexed citations

Naito, Yoichi, Seigo Nakamura, Nobuko Kawaguchi‐Sakita, et al.. (2024). Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors. International Journal of Clinical Oncology. 29(11). 1684–1695. 4 indexed citations

Yamauchi, Hideko, Masakazu Toi, Shin Takayama, et al.. (2023). Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial. Breast Cancer. 30(4). 596–605. 5 indexed citations

Ji, Shuting, Asuka Suzuki, Yusuke Iwasaki, et al.. (2023). Functional evaluation of BRCA1/2 variants of unknown significance with homologous recombination assay and integrative in silico prediction model. Journal of Human Genetics. 68(12). 849–857. 1 indexed citations

Okano, Maiko, Tadashi Nomizu, Kazunoshin Tachibana, et al.. (2020). The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database. Journal of Human Genetics. 66(3). 307–314. 28 indexed citations

Nakayama, Ryohei, et al.. (2020). Diagnostic performance of coronal view in comparison with transverse view of three-dimensional automated breast ultrasound. Acta Radiologica. 62(1). 27–33. 3 indexed citations

10.

Saito, Yoshihiko, Atsuko Nishikawa, Aritoshi Iida, et al.. (2020). ADSSL1 myopathy is the most common nemaline myopathy in Japan with variable clinical features. Neurology. 95(11). e1500–e1511. 20 indexed citations

11.

Markopoulos, Christos, David M. Hyams, Henry Gómez, et al.. (2019). Multigene assays in early breast cancer: Insights from recent phase 3 studies. European Journal of Surgical Oncology. 46(4). 656–666. 20 indexed citations

12.

Kuwayama, Takashi, Seigo Nakamura, Naoki Hayashi, et al.. (2018). Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2− Early-stage Breast Cancer. Clinical Breast Cancer. 18(6). 474–480. 22 indexed citations

13.

Yoshida, Atsushi, Naoki Hayashi, Koyu Suzuki, et al.. (2017). Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer. Journal of Surgical Oncology. 116(8). 1021–1028. 48 indexed citations

14.

Hayashi, Naoki, Yuko Takahashi, Naoko Matsuda, et al.. (2017). The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype. Clinical Breast Cancer. 18(2). e219–e229. 22 indexed citations

15.

Iwata, Hiroji, Hirofumi Fujii, Norikazu Masuda, et al.. (2013). Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study. Breast Cancer. 22(2). 192–200. 7 indexed citations

16.

Kuroi, Katsumasa, Masakazu Toi, Shinji Ohno, et al.. (2013). Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG. Breast Cancer. 22(5). 486–495. 26 indexed citations

17.

Aogi, Kenjiro, Toshiaki Saeki, Seigo Nakamura, et al.. (2012). A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study). International Journal of Clinical Oncology. 18(4). 598–606. 5 indexed citations

18.

Hayashi, Naoki, Takayuki Iwamoto, Ana M. González-Angulo, et al.. (2011). Prognostic Impact of Phosphorylated HER-2 in HER-2+ Primary Breast Cancer. The Oncologist. 16(7). 956–965. 12 indexed citations

19.

Hayashi, Naoki, Seigo Nakamura, Yuji Shimoda, et al.. (2011). Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. International Journal of Clinical Oncology. 17(2). 96–104. 69 indexed citations

20.

Hayashi, Naoki, Seigo Nakamura, Hiroshi Yagata, et al.. (2011). Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. International Journal of Clinical Oncology. 16(5). 596–600. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact